title: Impact of weight loss on the metabolic syndrome.
abstract: OBJECTIVE
  To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two.
  
  
  METHODS
  Randomized, controlled, 1-year clinical trial.
  
  
  METHODS
  One hundred and eighty women and 44 men, 18-65 years of age, with a body mass index of 30-45 kg/m(2), free of uncontrolled hypertension or type 1 or 2 diabetes.
  
  
  METHODS
  Fifteen milligrams of sibutramine per day alone, lifestyle modification counseling alone, sibutramine plus lifestyle modification counseling or sibutramine plus brief lifestyle modification counseling.
  
  
  METHODS
  The metabolic syndrome, as defined by the Adult Treatment Panel III.
  
  
  RESULTS
  Before treatment, 34.8% of the participants had the metabolic syndrome. Metabolic syndrome was more prevalent in Caucasians than African Americans (42.5 vs 20.3%; P<0.03), in males than females (65.1 vs 34.9%; P<0.002) and in older (>44 years) than younger (</=44 years) participants (47.5 vs 20.8%; P<0.0001). After 1 year of treatment, a moderate decrease in weight (8.0+/-8.7 kg) resulted in significant reductions in the prevalence of metabolic syndrome from 34.8 to 27.2% of all participants (P<0.02). Logistic regression analyses indicated that for each 1 kg of weight lost, the odds of metabolic syndrome were reduced by 8% (CI=0.89-0.97; P<0.003). Lifestyle modification either alone (P<0.04), or in combination with sibutramine (P<0.05), significantly reduced the prevalence of metabolic syndrome compared with sibutramine alone. The group effect was removed after controlling for weight loss.
  
  
  CONCLUSIONS
  The metabolic syndrome was prevalent in over one-third of obese individuals who sought weight loss treatment, and the prevalence differed by age, sex and ethnicity. Moderate weight loss markedly reduced the odds of metabolic syndrome in this sample.
authors.affiliation: Brown Medical School/The Miriam Hospital, Providence, RI, USA. sphelan@lifespan.org
authors.forename: S
authors.initials: S
authors.lastname: Phelan
authors.forename: T A
authors.initials: TA
authors.lastname: Wadden
authors.forename: R I
authors.initials: RI
authors.lastname: Berkowitz
authors.forename: D B
authors.initials: DB
authors.lastname: Sarwer
authors.forename: L G
authors.initials: LG
authors.lastname: Womble
authors.forename: R K
authors.initials: RK
authors.lastname: Cato
authors.forename: R
authors.initials: R
authors.lastname: Rothman
mesh_terms: D000328:Adult; D000368:Aged; D001067:Appetite Depressants / Q000627:therapeutic use*; D003503:Cyclobutanes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000517:prevention & control*; D008875:Middle Aged; D009765:Obesity / Q000628:therapy*; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine